GleamWall
中文EN

MYGN MYRIAD GENETICS INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 899923 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.6%
TTM net income YoY67.8%
TTM EPS YoY69.0%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR—

Margins

Gross margin68.3%
Operating margin-14.3%
Net margin-16.1%
FCF margin—
EBITDA margin-10.0%

Returns

ROE-40.2%
ROA-19.3%
ROIC (approx.)-28.9%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets55.8%
Debt / equity0.45x
Current ratio1.98x
Interest coverage-6.90x

Cash quality & payout

Operating cash flow / net income0.15x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$202.70M$190.70M$200.40M$209.80M$205.70M$213.10M$195.90M$210.60M
Cost of revenue$65.00M$63.70M$62.80M$63.00M$61.90M$61.30M$61.70M$59.70M
Gross profit$137.70M$127.00M$137.60M$146.80M$143.80M$151.80M$134.20M$150.90M
R&D expense$26.50M$25.00M$27.10M$25.50M$28.20M$25.60M$27.50M$32.20M
SG&A expense$67.20M$57.80M$62.20M$55.60M$67.90M$66.80M$66.50M-$148.10M
Operating income-$39.90M-$38.90M-$30.70M-$5.70M-$23.30M-$329.20M-$29.00M-$39.00M
Interest expense$4.10M$4.10M$4.10M$4.40M$3.80M$1.50M$800,000$700,000
Pretax income-$43.60M-$42.60M-$34.10M-$8.90M-$26.20M-$330.60M-$29.40M-$39.10M
Income tax$300,000$600,000$0-$1.00M$1.20M-$100,000-$29.30M$3.40M
Net income-$43.90M-$43.20M-$34.10M-$7.90M-$27.40M-$330.50M-$100,000-$42.50M
EBITDA-$35.00M-$34.10M-$18.20M$6.90M-$18.50M-$324.30M-$14.60M-$24.20M
EPS (basic)-0.46-0.46-0.36—-0.29-3.570.00—
EPS (diluted)-0.46-0.46-0.36—-0.29-3.570.00—
Weighted avg. shares (diluted)95.70M94.80M93.70M—93.10M92.50M91.40M—
Balance sheet
Cash & equivalents$107.10M$115.20M$124.40M$149.60M$145.40M$74.40M$91.80M$111.90M
Short-term investments———————$0
Receivables$105.50M$109.50M$123.80M$115.30M$118.00M$137.00M$120.40M$121.20M
Inventory$28.60M$30.60M$27.90M$30.60M$31.60M$28.70M$28.30M$27.50M
Current assets$271.90M$289.00M$312.80M$332.60M$344.80M$284.30M$287.20M$298.00M
PP&E, net$104.70M$108.90M$111.50M$114.00M$111.40M$113.00M$114.00M$117.40M
Goodwill$47.10M$47.10M$47.10M$51.60M$51.60M$51.60M$286.30M$286.30M
Intangibles$131.80M$139.00M$145.70M$153.40M$163.10M$170.10M$257.50M$262.40M
Total assets$609.20M$638.90M$673.70M$706.60M$728.10M$677.30M$1.01B$1.03B
Current liabilities$137.60M$130.70M$130.20M$133.80M$148.00M$199.90M$151.10M$164.10M
Short-term debt—————$59.40M—$0
Long-term debt$121.10M$120.70M$120.30M$119.90M$119.50M$0$59.30M$39.60M
Total debt$121.10M$120.70M$120.30M$119.90M$119.50M$59.40M$59.30M$39.60M
Total liabilities$340.20M$335.00M$336.30M$338.60M$355.30M$289.20M$301.20M$326.50M
Shareholders' equity$269.00M$303.90M$337.40M$368.00M$372.80M$388.10M$704.90M$701.10M
Net debt$14.00M$5.50M-$4.10M-$29.70M-$25.90M-$15.00M-$32.50M-$72.30M
Shares outstanding95.70M95.60M94.40M93.50M93.10M93.10M92.20M91.30M
Cash flow statement
Operating cash flow-$6.50M-$8.30M-$15.70M$10.60M$21.10M-$13.60M-$16.30M$6.60M
Investing cash flow-$2.10M-$3.20M-$6.50M-$6.00M-$6.20M-$6.90M-$8.30M-$5.90M
Financing cash flow-$300,000$2.20M-$3.00M-$8.20M$56.20M$2.60M$13.60M$2.10M
Depreciation & amortization$4.90M$4.80M$12.50M$12.60M$4.80M$4.90M$14.40M$14.80M
Stock-based compensation$9.20M$7.20M$6.50M$2.80M$12.20M$10.70M$9.50M$10.90M

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.